Stay updated with breaking news from Ruby study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer. ....
Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer. ....